Relevant conflicts of interest/financial disclosures: Nothing to report.
Version of Record online: 27 MAY 2011
Copyright © 2011 Movement Disorder Society
Special Issue: 25th Anniversary
Volume 26, Issue 6, pages 1127–1133, May 2011
How to Cite
Shoulson, I. and Young, A. B. (2011), Milestones in Huntington disease. Mov. Disord., 26: 1127–1133. doi: 10.1002/mds.23685
Full financial disclosures and author roles may be found in the online version of this article.
- Issue online: 26 MAY 2011
- Version of Record online: 27 MAY 2011
- Manuscript Accepted: 27 JAN 2011
- Manuscript Received: 18 JAN 2011
- Huntington disease;
- experimental therapeutics;
There have been extraordinary advances in our knowledge of the underlying gene, the protein it encodes, various models of disease, and potential targets for effective therapies for Huntington disease. Huntington disease research has increased exponentially in the past 25 years, and we now understand many of the molecular mechanisms underlying the disease. Still, more work needs to be done before we have a full understanding of the pathophysiology of the disease. Clinical research on biomarkers and clinical trials on potential neuroprotective agents are underway. Here we review our progress in these areas over the last 25 years and speculate on what the next 25 years may hold. © 2011 Movement Disorder Society